title: [Invasive fungal infection in solid organ transplant].
abstract: Invasive fungal infections (IFI) represent a serious threat for patients undergoing solid organ transplantation (SOT). IFI in SOT has a significant incidence and mortality not due to negligence. The management of IFI in SOT involves specific recommendations and has been individualized to the type of transplant and patient. The current review presents an overview of epidemiology, diagnosis, treatment and prevention of IFI in TOS. Depending on risk factors for different IFIs and transplant type, this paper includes the main recommendations based on previous publications and on the opinion of the authors on the prophylaxis and treatment of these patients. These recommendations highlight epidemiology changes and the emergence of new antifungals. The current document has focused mainly on Candidaspp. and Aspergillusspp., with a special mention to the rest of yeasts and moulds that are common in SOT.
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Barcelona, España. joan.gavalda@vhir.org
authors.forename: Joan
authors.initials: J
authors.lastname: Gavaldà
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Meije
authors.forename: Óscar
authors.initials: Ó
authors.lastname: Len
authors.forename: Albert
authors.initials: A
authors.lastname: Pahissa
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control / Q000635:transmission; D058365:Candidiasis, Invasive / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control / Q000635:transmission; D015331:Cohort Studies; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D003453:Cryptococcosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control / Q000635:transmission; D004347:Drug Interactions; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D016377:Organ Transplantation / Q000009:adverse effects; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011292:Premedication; D012306:Risk
chemical_list: D000935:Antifungal Agents